Abstract
Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.
Original language | English |
---|---|
Pages (from-to) | 110-116 |
Number of pages | 7 |
Journal | Cleveland Clinic journal of medicine |
Volume | 88 |
Issue number | 2 |
DOIs | |
Publication status | Published - 01 Feb 2021 |
Externally published | Yes |
Bibliographical note
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.Keywords
- Anthracyclines
- Breast Neoplasms
- Cardiotoxicity/etiology
- Echocardiography
- Female
- Heart
- Heart Diseases
- Humans
Fingerprint
Dive into the research topics of 'Cardiac surveillance for anti-HER2 chemotherapy.'. Together they form a unique fingerprint.Student theses
-
Cardiovascular disease in patients with cancer or amyloidosis
Hussain, M. (Author), Collier, P. (Supervisor), Watson, C. (Supervisor) & Grieve, D. (Supervisor), Jul 2023Student thesis: Doctoral Thesis › Doctor of Philosophy